Healthcare Industry News: HSMN NewsFeed
News Release - July 18, 2017
BD Transforms Microbiology Urine TestingNew BD Kiestra™ Urine Culture App1 Drives Increased Lab Efficiency and Impacts Patient Management
FRANKLIN LAKES, N.J., July 18, 2017 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new technology that can automatically report and release negative urine cultures.
Every day, medical laboratory professionals spend a significant amount of time reviewing urine samples. Because up to 70 percent of these samples yield no growth or no significant growth, professionals devote more time to non-value-added tasks rather than to complex patient samples that require expert analysis.
The BD Kiestra™ urine culture app, together with BD BBL™ plated media, uses digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean caught and catheterized samples. Using the BD Kiestra™ ReadA™ compact's intelligent incubation and imaging device with high-throughput robotics to perform time series imaging, plates with no significant growth can be automatically released for disposal and the results reported to the customer's compatible laboratory information system (LIS). Plates with significant growth automatically go into a queue for clinician analysis.
The definition of significant growth can be customized using patient demographics and lab-directed rules, a feature unique to this BD solution. The automatic results generated by the application elevate the entire lab automation solution into a diagnostic results generating device.
"As one of the first applications using image analysis software, the urine culture app begins the transformation of microbiology practices today," said Steve Conly, vice president of microbiology for BD. "Being able to automatically release urine specimens with no growth or no significant growth will allow laboratories to focus on more relevant clinical tasks. BD is committed to helping improve laboratory efficiency and patient management through innovation and automated intervention."
The BD Kiestra™ urine culture app was validated in close collaboration with the University of Ljubljana (Slovenia) and the University of Heidelberg (Germany). This technology can be used on the BD Kiestra™ WCA (work cell automation) and the BD Kiestra™ TLA (total lab automation) solutions. For more information BD Kiestra lab automation solutions, please visit: bd.com/en-us/offerings/capabilities/lab-automation/.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.